Mirikizumab Shows Efficacy for Crohn's Disease
Data from the VIVID-1 trial indicate significant rates of deep remission among patients using the medication.
Updated on Oct. 15, 2026 in Diabetes
Live Poll
Should chronic disease treatment prioritize deep remission over simple symptom relief for your health?
A post hoc analysis of the VIVID-1 trial reveals that approximately 20 percent of patients with active Crohn's disease achieved corticosteroid-free deep remission after one year of mirikizumab treatment. The findings were presented at UEG Week 2026 in Barcelona.
Why it matters
Researchers noted that starting the treatment earlier in the disease course correlates with higher rates of deep remission, offering a potential path to improved patient outcomes. The FDA previously approved the interleukin-23p19 antagonist for active Crohn's disease in January 2025.
In the VIVID-1 trial of 579 treated patients, 20.6 percent reached PRO deep remission compared to 1.5 percent on placebo. Among those with no prior biologic failure, the remission rate reached 25.5 percent.
The players
FDA
The United States Food and Drug Administration is the federal agency responsible for regulating food, drugs, and medical devices.
UEG Week
United European Gastroenterology Week is a prominent medical congress that brings together specialists to discuss advances in digestive health.
The details
The VIVID-1 study utilized a treat-through design that required corticosteroid-free clinical remission and endoscopic remission at week 52. Among participants achieving PRO deep remission, 87.4 percent also met the criteria for quality of life remission.
Timeline
January 2025: The FDA approved mirikizumab for active Crohn's disease.
Week 52: Researchers assessed deep remission rates for trial participants.
October 17 to 20, 2026: Results were presented at UEG Week 2026 in Barcelona.
The Big Picture
This analysis of the VIVID-1 phase 3 trial provides a granular look at treatment efficacy, shifting the focus from general clinical response to the achievement of deep, corticosteroid-free remission.
Patients with Crohn's disease may see mirikizumab as a more effective treatment option, particularly when initiated early in the disease course. Those currently managing the condition should consult their gastroenterologist about how these remission statistics apply to their specific medical history.
The takeaway
Early medical intervention remains a critical factor in managing Crohn's disease effectively. Patients should prioritize consistent communication with their medical providers to determine if new therapies like mirikizumab align with their specific clinical needs.
Further reading
Learn more about the latest research and management strategies in the Diabetes section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should chronic disease treatment prioritize deep remission over simple symptom relief for your health?
